ILC2 Differentiation Using CDK8 Inhibitors From iPS Precursors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a limited supply of ILC2s or ILC precursor cells that can be isolated from human peripheral blood, making them difficult to use as a source for cell therapy, and no method exists for inducing ILC2s from induced pluripotent stem cells (iPS cells).

Innovation Solution

A method involving culturing hematopoietic precursor cells in the presence of CDK8 inhibitors, such as Senexin A, CCT-251921, or IL-33, to differentiate them into group 2 innate lymphoid cells, including IL-10-producing ILC2s, using pluripotent stem cells like iPS cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If ILC2s are isolated from human peripheral blood, then the cells can be used for therapy, but the supply is quantitatively limited

Engineering Contradiction:

Improvesupply of ILC2sVSAvoiddifficulty to use as source for cell therapy

Core Design Contradiction:

Quantity of substanceVSEase of manufacture

Solution Approach 1:

The patent applies preliminary action by inducing ILC2s from pluripotent stem cells (iPS cells) in advance, creating a renewable source of ILC2s before they are needed for therapy. This involves culturing iPS cells and inducing their differentiation into ILC2s through controlled culture conditions, thereby establishing a preparatory supply chain that eliminates the limitation of isolating ILC2s from peripheral blood at the time of therapy need.

Inventive Principle:

Principle #10Preliminary action

2Productivity

If a method for inducing ILC2s from pluripotent stem cells is developed, then unlimited proliferation is enabled, but no such method has been reported yet

Engineering Contradiction:

Improveproduction capacity of ILC2sVSAvoidlack of established method

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying culture conditions to induce ILC2 differentiation from iPS cells. Specific parameters including culture medium composition, growth factors, and incubation conditions are adjusted to guide the differentiation process. This systematic modification of cultural parameters establishes a reproducible method for generating ILC2s from pluripotent stem cells, enabling unlimited production capacity.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If ILC2s are used for cell therapy, then therapeutic effect is achieved, but the limited supply makes it difficult to meet therapeutic demands

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidavailability of ILC2s

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies copying by generating multiple copies of ILC2s through the differentiation of pluripotent stem cells. Instead of relying on the limited natural supply of ILC2s from peripheral blood, the method creates numerous identical or similar functional cells from a renewable iPS cell source, thereby ensuring sufficient quantity for therapeutic applications while maintaining the reliability and therapeutic effectiveness of the original ILC2s.

Inventive Principle:

Principle #26Copying

Data Source

PatentEP4700116A1Method for producing type 2 innate lymphocytes

Publication Date: 2026.02.25 ASTELLAS PHARMA INC

Figure 2~1-2
Figure 4~3-2
Figure 5~6

AI summary

The present invention is directed to establishing a technique for producing group 2 innate lymphoid cells. Culturing hematopoietic precursor cells in the presence of CDK8 inhibitor enables to obtain group 2 innate lymphoid cells.